Dr Melanie Ashton

Patterns of pharmacotherapy for bipolar disorder: A GBC survey

B Singh, A Yocum, R Strawbridge, K Burdick, C Millett, A Peters, S Sperry, G Fico, E Vieta, N Verdolini, O Godin, M Leboyer, B Etain, I Tso, B Coombes, M McInnis, A Nierenberg, A Young, M Ashton, M Berk, L Williams, K Keramatian, L Yatham, B Overs, J Fullerton, G Roberts, P Mitchell, O Andreassen, A Andreazza, P Zandi, D Pham, J Biernacka, M Frye

(2024), Vol. 26, pp. 22-32, Bipolar Disorders, C1

Exploring Clinical Subgroups of Participants with Major Depressive Disorder that May Benefit from Adjunctive Minocycline Treatment

Gerard Anmella, Alcy Meehan, Melanie Ashton, Mohammadreza Mohebbi, Giovanna Fico, Chee Ng, Michael Maes, Lesley Berk, Michele Prisco, Ajeet Singh, Gin Malhi, Michael Berk, Seetal Dodd, Diego Hidalgo-Mazzei, Iria Grande, Isabella Pacchiarotti, Andrea Murru, Eduard Vieta, Olivia Dean

(2024), Vol. 22, pp. 33-44, Clinical Psychopharmacology and Neuroscience, Yeongdeungpo-gu, Seoul, C1

Trauma and comorbid post-traumatic stress disorder in people with bipolar disorder participating in the Heinz C. Prechter Longitudinal Study

S Russell, A Wrobel, M Lotfaliany, M Ashton, R Kaur, A Yocum, E Duval, C Diaz-Byrd, T Ehrlich, D Marshall, M Berk, M McInnis, O Dean, A Turner

(2024), Vol. 348, pp. 275-282, Journal of Affective Disorders, Netherlands, C1

The Impact of Posttraumatic Stress Disorder on Pharmacologic Intervention Outcomes for Adults With Bipolar Disorder: A Systematic Review

S Russell, A Wrobel, D Skvarc, B Kavanagh, M Ashton, O Dean, M Berk, A Turner

(2023), Vol. 26, pp. 61-69, The international journal of neuropsychopharmacology, C1

Adjunctive minocycline for major depressive disorder: A sub-study exploring peripheral immune-inflammatory markers and associated treatment response

A Walker, M Mohebbi, M Maes, M Berk, K Walder, C Bortolasci, Z Liu, C Ng, M Ashton, L Berk, A Singh, G Malhi, O Dean

(2023), Vol. 27, Brain, Behavior, and Immunity - Health, C1

The Impact of N-acetylcysteine on Major Depression: Qualitative Observation and Mixed Methods Analysis of Participant Change during a 12-week Randomised Controlled Trial

Samantha Russell, David Skvarc, Mohammadreza Mohebbi, David Camfield, Linda Byrne, Alyna Turner, Melanie Ashton, Michael Berk, Seetal Dodd, Gin Malhi, Sue Cotton, Ashley Bush, Olivia Dean

(2023), Vol. 21, pp. 320-331, Clinical Psychopharmacology and Neuroscience, Seoul, Korea, C1-1

Metabolic regulation to treat bipolar depression: mechanisms and targeting by trimetazidine

S Khanra, P Reddy, A Giménez-Palomo, C Park, B Panizzutti, M McCallum, S Arumugham, S Umesh, M Debnath, B Das, G Venkatasubramanian, M Ashton, A Turner, O Dean, K Walder, E Vieta, L Yatham, I Pacchiarotti, Y Reddy, N Goyal, M Kesavan, L Colomer, M Berk, J Kim

(2023), Vol. 28, pp. 3231-3242, Molecular Psychiatry, C1

Does Post-traumatic Stress Disorder Impact Treatment Outcomes within a Randomised Controlled Trial of Mitochondrial Agents for Bipolar Depression?

Samantha Russell, Anna Wrobel, Melanie Ashton, Alyna Turner, Mohammadreza Mohebbi, Michael Berk, Sue Cotton, Seetal Dodd, Chee Ng, Gin Malhi, Olivia Dean

(2023), Vol. 21, pp. 457-465, Clinical Psychopharmacology and Neuroscience, Seoul, Korea, C1

Coping with COVID-19: Exploring coping strategies, distress, and post-traumatic growth during the COVID-19 pandemic in Australia

B Kavanagh, J O’Donohue, M Ashton, M Lotfaliany, M McCallum, A Wrobel, S Croce, M Berk, L Saunders, J Lai, L Berk

(2022), Vol. 13, Frontiers in Psychiatry, Switzerland, C1

A Systematic Review of Nutraceuticals for the Treatment of Bipolar Disorder

M Ashton, B Kavanagh, W Marx, M Berk, J Sarris, C Ng, M Hopwood, L Williams, O Dean

(2021), Vol. 66, pp. 262-273, Canadian Journal of Psychiatry, United States, C1

Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials

R Zazula, M Husain, M Mohebbi, A Walker, I Chaudhry, A Khoso, M Ashton, B Agustini, N Husain, J Deakin, A Young, M Berk, B Kanchanatawan, C Ng, M Maes, L Berk, A Singh, G Malhi, O Dean

(2021), Vol. 55, pp. 784-798, Australian and New Zealand Journal of Psychiatry, England, C1

Systematic review and meta-analysis of the role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders

B Kavanagh, M Ashton, S Cowdery, O Dean, A Turner, M Berk, S Gwini, S Brennan-Olsen, H Koivumaa-Honkanen, A Chanen, L Williams

(2021), Vol. 279, pp. 711-721, Journal of affective disorders, Amsterdam, The Netherlands, C1

Adjunctive Garcinia mangostana Linn. (Mangosteen) Pericarp for Schizophrenia: A 24-Week Double-blind, Randomized, Placebo Controlled Efficacy Trial: Péricarpe d'appoint Garcinia mangostana Linn (mangoustan) pour la schizophrénie : un essai d'efficacité de 24 semaines, à double insu, randomisé et contrôlé par placebo

A Turner, A Baker, O Dean, A Walker, S Dodd, S Cotton, J Scott, B Kavanagh, M Ashton, E Brown, J McGrath, M Berk

(2021), Vol. 66, pp. 354-366, Canadian Journal of Psychiatry, United States, C1

Plant-based Medicines (Phytoceuticals) in the Treatment of Psychiatric Disorders: A Meta-review of Meta-analyses of Randomized Controlled Trials: Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: une méta-revue des méta-analyses d'essais randomisés contrôlés

J Sarris, W Marx, M Ashton, C Ng, N Galvao-Coelho, Z Ayati, Z Zhang, S Kasper, A Ravindran, B Harvey, A Lopresti, D Mischoulon, J Amsterdam, L Yatham, M Berk

(2021), Vol. 66, pp. 849-862, Canadian Journal of Psychiatry, United States, C1

The Effect of Adjunctive Mangosteen Pericarp on Cognition in People With Schizophrenia: Secondary Analysis of a Randomized Controlled Trial

W Marx, D Skvarc, M Mohebbi, A Walker, A Meehan, A Turner, A Baker, S Dodd, S Cotton, J Scott, B Kavanagh, M Ashton, E Brown, J McGrath, M Berk, O Dean

(2021), Vol. 12, Frontiers in Psychiatry, Switzerland, C1

Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial

C Bortolasci, A Turner, M Mohebbi, Z Liu, M Ashton, L Gray, W Marx, A Walker, G Kowalski, F Jacka, M Berk, O Dean, K Walder

(2021), Vol. 142, pp. 376-383, Journal of Psychiatric Research, England, C1

Exploring interleukin-6, lipopolysaccharide binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression

K Hasebe, M Mohebbi, L Gray, A Walker, C Bortolasci, A Turner, M Berk, K Walder, M Maes, B Kanchanatawan, M Ashton, L Berk, C Ng, G Malhi, A Singh, O Dean

(2021), Vol. 34, Acta Neuropsychiatrica, England, C1

Personality disorder and functioning in major depressive disorder: a nested study within a randomized controlled trial

Bianca Kavanagh, Lana Williams, Michael Berk, Alyna Turner, Henry Jackson, Mohammadreza Mohebbi, Buranee Kanchanatawan, Melanie Ashton, Chee Ng, Michael Maes, Lesley Berk, Gin Malhi, Nathan Dowling, Ajeet Singh, Olivia Dean

(2020), Vol. 42, pp. 14-21, Brazilian journal of psychiatry, Sao Paulo, Brazil, C1

Diet quality, dietary inflammatory index and body mass index as predictors of response to adjunctive N-acetylcysteine and mitochondrial agents in adults with bipolar disorder: a sub-study of a randomised placebo-controlled trial

M Ashton, O Dean, W Marx, M Mohebbi, M Berk, G Malhi, C Ng, S Cotton, S Dodd, J Sarris, M Hopwood, K Faye-Chauhan, Y Kim, S Dash, F Jacka, N Shivappa, J Hebert, A Turner

(2020), Vol. 54, pp. 159-172, Australian and New Zealand journal of psychiatry, London, Eng., C1

Physical activity as a predictor of clinical trial outcomes in bipolar depression: a subanalysis of a mitochondrial-enhancing nutraceutical randomized controlled trial

M Ashton, M Mohebbi, A Turner, W Marx, M Berk, G Malhi, C Ng, S Cotton, S Dodd, J Sarris, M Hopwood, B Stubbs, O Dean

(2020), Vol. 65, pp. 306-318, Canadian journal of psychiatry, London, Eng., C1

Prebiotics, probiotics, fermented foods and cognitive outcomes: A meta-analysis of randomized controlled trials

Wolfgang Marx, Andrew Scholey, Joseph Firth, Nathan D’Cunha, Melissa Lane, Meghan Hockey, Melanie Ashton, John Cryan, A O'Neil, Nenad Naumovski, Michael Berk, Olivia Dean, Felice Jacka

(2020), Vol. 118, pp. 472-484, Neuroscience & Biobehavioral Reviews, Amsterdam, The Netherlands, C1

Efficacy of adjunctive Garcinia mangostana Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trial

Melanie Ashton, Michael Berk, Chee Ng, Malcolm Hopwood, Seetal Dodd, Alyna Turner, Ellie Brown, Felice Jacka, Susan Cotton, Jon-Paul Khoo, Mary Chatterton, Bianca Kavanagh, Sarah Nadjidai, Samantha Lo Monaco, Brian Harvey, Jerome Sarris, Gin Malhi, Nathan Dowling, Olivia Dean

(2019), Vol. 41, pp. 245-253, Brazilian journal of psychiatry, Sao Paulo, Brazil, C1

The therapeutic potential of mangosteen pericarp as an adjunctive therapy for bipolar disorder and schizophrenia

M Ashton, O Dean, A Walker, C Bortolasci, C Ng, M Hopwood, B Harvey, M Möller, J McGrath, W Marx, A Turner, S Dodd, J Scott, J Khoo, K Walder, J Sarris, M Berk

(2019), Vol. 10, Frontiers in Psychiatry, Switzerland, C1

Protocol and rationale: a 24-week double-blind, randomized, placebo controlled trial of the efficacy of adjunctive garcinia mangostanaLinn. (mangosteen) pericarp for schizophrenia

Alyna Turner, John McGrath, Olivia Dean, Seetal Dodd, Andrea Baker, Susan Cotton, James Scott, Bianca Kavanagh, Melanie Ashton, Adam Walker, Ellie Brown, Michael Berk

(2019), Vol. 17, pp. 297-307, Clinical psychopharmacology and neuroscience, Seoul, South Korea, C1

Nutraceuticals and nutritional supplements for the treatment of bipolar disorder: Protocol for a systematic review

M Ashton, M Berk, C Ng, M Hopwood, B Kavanagh, L Williams, J Sarris, O Dean

(2019), Vol. 9, BMJ Open, England, C1

Role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders: A protocol for a systematic review and meta-analysis

B Kavanagh, S Brennan-Olsen, A Turner, O Dean, M Berk, M Ashton, H Koivumaa-Honkanen, L Williams

(2019), Vol. 9, BMJ Open, England, C1

Mitochondrial agents for bipolar disorder

C Pereira, V Chavarria, J Vian, M Ashton, M Berk, W Marx, O Dean

(2018), Vol. 21, pp. 550-569, International Journal of Neuropsychopharmacology, England, C1

Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology

J Data-Franco, A Singh, D Popovic, M Ashton, M Berk, E Vieta, M Figueira, O Dean

(2017), Vol. 72, pp. 73-86, Progress in neuro-psychopharmacology & biological psychiatry, Amsterdam, The Netherlands, C1

Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial

O Dean, B Kanchanatawan, M Ashton, M Mohebbi, C Ng, M Maes, L Berk, A Sughondhabirom, S Tangwongchai, A Singh, H McKenzie, D Smith, G Malhi, N Dowling, M Berk

(2017), Vol. 51, pp. 829-840, Australian and New Zealand Journal of Psychiatry, England, C1

Staging in bipolar disorder: from theoretical framework to clinical utility

M Berk, R Post, A Ratheesh, E Gliddon, A Singh, E Vieta, A Carvalho, M Ashton, L Berk, S Cotton, P McGorry, B Fernandes, L Yatham, S Dodd

(2017), Vol. 16, pp. 236-244, World psychiatry, Chichester, Eng., C1

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: a 16-week open-label pilot study

R Menon, L Cribb, J Murphy, M Ashton, G Oliver, N Dowling, A Turner, O Dean, M Berk, C Ng, J Sarris

(2017), Vol. 4, pp. 109-114, Advances in integrative medicine, Amsterdam, The Netherlands, C1

Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial.

O Dean, O Dean, M Maes, M Maes, M Ashton, M Ashton, L Berk, L Berk, B Kanchanatawan, B Kanchanatawan, A Sughondhabirom, A Sughondhabirom, S Tangwongchai, S Tangwongchai, C Ng, C Ng, N Dowling, N Dowling, G Malhi, G Malhi, M Berk, M Berk

(2014), Vol. 12, pp. 180-188, Clinical psychopharmacology and neuroscience, Seoul, Korea, C1